For Immediate Release

CiNTL Pharma B.V. Announces New Advisory Board to Drive AI-Powered Clinical Research Innovation

May 13, 2024

Leiden, The Netherlands, May 13, 2024 – In a strategic move to accelerate innovation and solidify its leadership in clinical research, CiNTL Pharma B.V. is proud to announce the formation of its new Advisory Board. This distinguished panel of experts brings together a unique combination of therapeutic specialists and visionary leaders in Artificial Intelligence (AI) and Machine Learning (ML), all committed to scaling CiNTL.AI—CiNTL Pharma’s groundbreaking software solution currently undergoing patent approval.

“At CiNTL Pharma, we are dedicated to pushing the boundaries of clinical research through innovation and technology,” said Yolanda Cabrera-Sybesma, Chief Executive Officer of CiNTL Pharma B.V. “With the expertise of our newly appointed Advisory Board, we are poised to integrate AI-driven solutions that will enhance the efficiency, accuracy, and scalability of clinical trials, ultimately delivering better patient outcomes and streamlined drug development processes.”

The Advisory Board comprises world-class professionals across key therapeutic areas, including biosimilars, oncology, endocrinology, gastroenterology, infectious diseases, rare diseases, respiratory health, and reproductive health. Additionally, the inclusion of AI and ML specialists will play a critical role in optimizing CiNTL.AI’s capabilities, ensuring that the platform remains at the forefront of intelligent clinical trial management.

CiNTL.AI is designed to revolutionize the clinical trial landscape by leveraging AI-powered analytics, predictive modeling, and automated workflows. By integrating cutting-edge data science with deep industry expertise, the software aims to provide pharmaceutical and biotechnology companies with unprecedented insights and efficiency in clinical research management.

“With the convergence of AI and clinical research, CiNTL Pharma is committed to shaping the future of drug development,” added Cabrera-Sybesma. “We believe that by harnessing the power of data and innovation, we can drive meaningful change in the industry and ensure faster, more reliable, and cost-effective clinical trials.”

For more information about CiNTL Pharma B.V. and its commitment to AI-driven clinical research innovation, visit www.cintlpharma.com.

CiNTL Pharma B.V. is a Contract Research Organization (CRO) that provides clinical research development, consultancy and data driven solution services to the pharmaceutical, biotechnology and life sciences industries.

For media inquiries, partnerships, or collaborations, please contact CiNTL Pharma Business Development at BD@cintlpharma.com.

Witness the future of intelligent clinical research – Experience CiNTL Pharma today.